Our VCX™ Discovery Platform is a high throughput screening platform and process for evaluating new drug candidates (chemical, botanical, or biological entities). The adaptability of the platform is based on personalized consultation with clients to identify disease target of interest, optimized cell based models of pathophysiology, targeted mixing and matching of key cellular assays to define therapeutic benefit, and ultimate screening and candidate identification based on defined machine learning analysis based on proprietary in house validated data on reference drug targets. Additional scale and disease/target validation to screening is offered by enhanced testing in C. elegans, a model organism, for a variety of processes.
The VCX™ Discovery Platform is a scalable system that saves millions of dollars in the drug discovery process consumed by sup-prime models and assays, time to screen, and poorly identified candidate compounds. The VCX Platform de-risks the discovery and development process by providing a means of assessing the therapeutic potential of hundreds of compounds over a short period of time, generating data in months, not years.
With the completion of the development of the VCX Discovery Platform and filing of IP, Verséa Discovery is now begin screening hemp-derived and pharmaceutical compounds to build a pipeline of New Chemical Entities (NCEs) and Botanical Rx drug candidates using standard as well as personalized based in vitro model systems. Areas of interest and available models at Verséa Discovery include: